Cretostimogene Grenadenorepvec not checked
CG Oncology, Inc. · CG0070
FollowEvery change as it happens, and a Monday email
Trials
3 active
7 in total
Targets
—
None known yet
What this is
- How it works
- A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
- Tested for
- Non Muscle Invasive Bladder Cancer (2 trials), Urologic Cancer, Bladder Cancer, Urothelial Carcinoma, High-grade Ta/ T1 Papillary Disease Bladder Cancer, High-Risk Non-Muscle-Invasive Bladder Cancer
- Main trialPhase 3
- “This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.”In the company’s words, NCT06111235 on ClinicalTrials.gov
- Other names
- CG0070 · oncolytic virus · GM-CSF expression · adenoviral vector · Adenovirus with GMCSF expression · DDM
Other drugs for Non Muscle Invasive Bladder Cancer
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- NDV-01Relmada Therapeutics, Inc. · Phase 3
- TAR-210Johnson & Johnson (Janssen) · Phase 3
- TARA-002Protara Therapeutics · Phase 3
- Alpha1HHamlet Pharma AB · Phase 3
- SasanlimabPfizer · Phase 3
Coming up3
- NovPhase 3 trial completes · ClinicalTrials.gov
- 31 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- 16 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Nov 2026 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | |
| Phase 3Active, not recruiting | 16 Jun 2030 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | |
| Phase 2Recruiting | 31 Mar 2027 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | |
| Phase 2/3Terminated | Jun 2016 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer | |
| Phase 2Withdrawn | Mar 2015 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer | |
| Phase 2Completed | Aug 2018 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure | |
| Phase 2Completed | 7 Mar 2023 | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026